The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2023
Filed:
Nov. 09, 2020
Applicant:
The Regents of the University of California, Oakland, CA (US);
Inventors:
Thomas J. Kipps, San Diego, CA (US);
Jianqianq Yu, San Diego, CA (US);
Assignee:
The Regents of the University of California, Oakland, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); C07K 14/725 (2006.01); C07K 16/40 (2006.01); C07K 16/46 (2006.01); C07K 14/705 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/40 (2013.01); C07K 16/46 (2013.01); C07K 16/468 (2013.01); G01N 33/57492 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01); G01N 2333/705 (2013.01);
Abstract
Compositions including an antibody single-chain variable fragment (scFv) conjugate that specifically binds to ROR1 tumor-associated antigen are provided. The anti-ROR1 scFv antibody and conjugates may include a biologically-active molecule. Such conjugates may comprise a chimeric receptor to direct T cells to respond to ROR1 cancer cells, Methods to use the scFV conjugates to target cells expressing ROR1 for therapeutic and diagnostic purposes are also provided.